HomeSGX-LISTED COMPANIESReclaims Global: Half-Year Financials and Dividend Announcement 1H2026

Reclaims Global: Half-Year Financials and Dividend Announcement 1H2026

Published on

spot_img

Reclaims Global Limited, an eco-friendly integrated service provider in the construction industry, experienced an increase in overall revenue for the first half of the financial year 2026, driven by strong market demand in certain segments. Despite this, its recycling operations faced a downturn. The company also saw notable reclassifications within its assets and managed shifts in operational expenses during this period.

• Discover how market dynamics influenced the performance of the company’s distinct business areas

• Uncover significant changes in the composition of the company’s financial holdings

• Explore the underlying reasons for shifts in the company’s operational earnings

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...